A Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy Phase II Trial to Evaluate the Efficacy and Safety of the Combinations of Lercanidipine and Valsartan in Comparison to Each Component Administered Alone and to Determine the Optimal Dose Combinations in Patients With Essential Hypertension.

Trial Profile

A Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy Phase II Trial to Evaluate the Efficacy and Safety of the Combinations of Lercanidipine and Valsartan in Comparison to Each Component Administered Alone and to Determine the Optimal Dose Combinations in Patients With Essential Hypertension.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2014

At a glance

  • Drugs Lercanidipine/valsartan (Primary) ; Lercanidipine; Valsartan
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors LG Life Sciences
  • Most Recent Events

    • 17 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 May 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top